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Abstract
Background/Aims: The transient receptor potential cation channel subfamily C member 6 
(TRPC6) is a Ca2+-permeable nonselective cation channel and has received recent attention 
because of its capability to promote chronic kidney disease (CKD). The aims of this study 
were (i) to examine whether deletion of TRPC6 impacts on renal fibrosis and inflammatory 
cell infiltration in an early CKD model of unilateral ureter obstruction (UUO) in mice; and (ii) 
whether TRPC6-deficiency as well as UUO affect the regulation of TRPC expression in murine 
kidneys. Methods: Wild-type (WT), Trpc6-knockout (Trpc6-/-) and New Zealand obese (NZO) 
mice underwent sham operation or unilateral ureteral obstruction (UUO). The kidneys were 
harvested 7 days after surgery. We examined renal fibrosis and inflammatory cell infiltration by 
histological and immunohistochemical staining. The mRNA expression of TRPC members and 
markers of fibrosis and inflammation in kidney were assessed by using real-time quantitative 
reverse transcription PCR. Results: Histological and immunohistochemical analyses revealed 
less inflammatory cell infiltration (F4/80 and CD3) in UUO kidneys of Trpc6-/- mice compared to 
UUO kidneys of WT mice as well as less fibrosis. Genomic deletion of TRPC6 also affected the 
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expression of pro-fibrotic genes in UUO Trpc6-/- kidneys compared to UUO WT kidneys while 
the expression of pro-inflammatory genes did not differ. UUO caused marked up-regulation 
of Trpc6 and down-regulation of Trpc1 mRNA in kidneys of WT and NZO mice. Trpc3 mRNA 
expression was significantly elevated in kidneys of Trpc6-/- mice underwent UUO while the 
levels did not change in kidneys of neither WT nor in NZO mice underwent UUO. Conclusion: 
TRPC6 contributes to renal fibrosis and immune cell infiltration in the UUO mouse model. 
Therefore, inhibition of TRPC6 emerges as a promising novel therapeutic strategy for treatment 
of chronic kidney failure in chronic obstructive nephropathy. However, confounding genomic 
and non-genomic effects of other TRPC channels should be taken into consideration to fully 
comprehend the renoprotective potential of targeting TRPC6 therapeutically under chronic 
kidney damaging conditions.
Introduction
Renal fibrosis is the inevitable consequence of an excessive accumulation of extracellular 
matrix that occurs in virtually every type of chronic kidney disease (CKD) irrespective of the 
underlying etiology [1]. Renal fibrosis is the principal process underlying the progression of 
CKD to end-stage renal disease. It is characterized by glomerulosclerosis and tubulointerstitial 
fibrosis, and by deposition of excess matrix in the interstitial space surrounding tubules 
and peritubular capillaries, coupled with the appearance of interstitial fibroblasts [2]. The 
initiation and progression of renal fibrosis appear to involve a complex, so far incompletely 
characterized, interaction between injured tubules, pericytes, fibroblasts, endothelial cells 
and inflammatory cells [2, 3]. Considerable efforts are being made to identify novel drug 
targets to prevent or halt renal fibrosis, the final common pathway of a wide variety of CKD.
The unilateral ureteral obstruction (UUO) model is a standard and widely used 
experimental model of renal interstitial fibrosis (for review see [4]). Ureteral obstruction 
results in marked renal hemodynamic and metabolic changes, followed by tubular injury 
and cell death by apoptosis or necrosis, in conjunction with an infiltration of macrophages 
and other inflammatory cells into the renal interstitium. Proliferation of fibroblasts and 
transformed myofibroblasts produce excessive extracellular matrix leading to accelerated 
renal fibrosis. Phenotypic transition of resident renal tubular cells, endothelial cells, and 
pericytes has also been implicated in this process [4].
Transient receptor potential (TRP) channels have been implicated in renal fibrosis. 
The classical or canonical TRP channels (TRPCs) are the subfamily most closely related to 
the founding member of the TRP family, the Drosophila TRP channel [5, 6]. TRPCs are Ca2+-
permeable nonselective cation channels encoded by Trpc1-7. While most TRPC subunits can 
form functional homomeric channels, heteromerization of TRPC channel subunits of either 
the same subfamily or different subfamilies has been widely observed to extend functional 
diversity [7-12].
TRPC6 is widely expressed in renal tissues, including glomerular podocytes, mesangial 
cells, endothelial cells, tubulointerstitial vascular and epithelial cells, as well as renal 
blood vessels [13]. TRPC6 is one of the podocyte slit-diaphragm proteins associated with 
proteinuria, which is mainly mediated by Ca2+ influx [14]. TRPC6, nephrin, podocin and CD2-
associated protein directly or indirectly interact with α-actinin-4 to maintain the integrity of 
the glomerular filtration barrier [14, 15]. Podocyte TRPC6 channels play a role in inherited 
focal segmental glomerulosclerosis (FSGS) [6]. Moreover, angiotensin II (Ang II), known as 
an important causal driver of chronic kidney disease, can rapidly activate and upregulate the 
expression of TRPC6 in podocytes. As a result, the intracellular Ca2+ concentration increases 
and eventually leads to podocyte apoptosis and progressive kidney failure [16, 17].
Interestingly, up-regulation of both TRPC3 and TRPC6 expression has been reported 
in UUO kidneys [18]. It is suggested that up- or downregulation of other TRPCs could 
possibly play critical roles in kidneys. For another example, diabetic kidneys show reduced 
TRPC1 expression [19], which together with increased TRPC6 activity in podocytes could 
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contribute to glomerulopathy [20-22]. Given that the TRPCs have the ability to form homo- 
and heteromers, it is very likely that other TRPC family members additionally contribute to 
the formation of nephropathy in mouse and man.
The metabolic syndrome characterized by hypertension, hypoglycemia and lipedema is 
a complex disease leading to chronic kidney disease and fibrosis, as well. The New Zealand 
Obese (NZO) mouse represents one of the most thoroughly investigated polygenic models 
for the human metabolic syndrome and type 2 diabetes. It presents the main characteristics 
of the disease complex, including early-onset obesity, insulin resistance, dyslipidemia, and 
hypertension [23-25]. To the best of our knowledge, no studies have been reported on renal 
expression of TRPC channels in this model and their putative role in CKD progression.
We tested the hypothesis that up-regulation of renal TRPC6 is a common feature in renal 
fibrosis and immune cell infiltration in mice. We used the UUO model to induce renal fibrosis, 
immune cell infiltration and analyzed the expression of TRPC channels in the kidneys of 
wild-type (WT) and Trpc6-knockout (Trpc6-/-) mice. Further we used the NZO mouse model 
[23-26] to evaluate UUO nephropathy as well as the regulation of TRPC channel expression 
in an inbred obese mouse strain carrying susceptibility genes for diabetes and hypertension.
Materials and Methods
Animals
Male Trpc6-/- mice (24.51±2.73 g body weight (b.w.), n=31, 9-12 weeks old) and age-matched 
WT controls (25.69±1.79 g b.w., n=32, p>0.05) were used. The Trpc6-/- mice have been generated on 
C57BL/6J:129/Sv genetic background and characterized previously [27]. Since 129Sv and C57BL/6J mice 
display similar renal damage in the UUO model [28], we chose C57BL/6J mice as control Trpc6+/+ (WT) mice. 
Age-matched male NZO mice from our own colony were used, which were obese (39.90±4.11 g b.w., n=15, 
p<0.05 vs. both WT and Trpc6-/- mice) and carry susceptibility genes (from the NZO/BomHIDife genetic 
background) for obesity, diabetes and hypertension [23-26]. The mice were housed in groups of three to five 
and single housing was applied 7 days before and after the UUO surgery to assure uniformity. The mice were 
reared under specific pathogen free (SPF)-conditions in individually ventilated cages (IVC) with a diurnal 
12 h light and dark cycle (lights on at 06:00 h) at a temperature of 21±1°C. All animals had free access to 
water and food. The mice were housed and handled in unity with good animal practice as defined by the 
Federation of European Laboratory Animal Science Associations (FELASA) [29] and the national welfare 
body GV-SOLAS [30]. Animal care followed American Physiological Society guidelines [31]. All animal 
protocols were approved by local authorities (Landesamt für Umwelt, Gesundheit und Verbraucherschutz 
(LUGV) Brandenburg, Germany; Permit-Number: 2347-7-2016).
UUO model
All surgical procedures were performed under aseptic conditions. The mice were anesthetized with 
2% isoflurane and placed on a heating pad to prevent hypothermia. After the depth of anaesthesia was 
confirmed by a loss of reflexes (toe pinch) the anterior abdominal skin was shaved, wiped off with 70% 
ethanol and 500 mg/kg metamizole (500 mg/ml, WDT) was injected intraperitoneally (i.p.). Eventually a 
midline laparotomy was conducted via an incision of the avascular linea alba and the left ureter was exposed. 
The ureter was then ligated twice close to the renal pelvis using a 5-0 polyglycolic acid (PGA) suture wire 
(Resorba®), and subsequently, 0.05 ml of a 10% enrofloxacine solution (Baytril, Bayer) was applied in the 
abdominal cavity. Sham operation was performed without ureteral ligation. The linea alba and skin were 
closed separately. The wound was sanitized with a silver aluminium spray (Henry Schein®) and 1 ml of 
warm (37°C) isotonic sodium chloride solution (Berlin-Chemie Menarini) was injected subcutaneously 
(s.c.). Subsequently, each mouse was placed in a cage in front of an infrared (IR) lamp and monitored 
until they recovered consciousness. For the following two days mice received metamizole (500 mg/ml, 
Lichtenstein) in their drinking water with a final concentration of 1.33 mg/ml. The tissue harvest occurred 
7 days after the surgeries (UUO and sham). For this, mice where sacrificed with an overdose of isoflurane (1 
ml/ml, CP-Pharma) and death was confirmed via a lack of reflex formation upon targeted provocation. Left 
kidneys were excised and decapsulated for further analysis. The kidneys were transversely divided into two 
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portions. Half of the kidney was immersed in a 4% phosphate-buffered paraformaldehyde (PFA) (Sigma) 
solution for histology, and the other half was snap-frozen in liquid nitrogen for RNA preparation.
Histology, immunohistochemistry and histological analyses
Paraffin-embedded kidneys were cut in three micrometer thick sections followed by deparaffination 
in sequential steps of xylene, ethanol solutions (100%, 96%, 70%) and a final rehydration step in water. For 
the morphological and histological analyses, Sirius red (SR) stains and Periodic acid Schiff (PAS) reactions 
were performed according to the manufacturer’s protocols (Sigma). SR specifically stains collagen type 1 
and 3 fibrils and allows a quantification of interstitial fibrosis. The PAS reaction visualizes the basement 
membranes of the capillary loops of the glomeruli through which the glomerular damage can be evaluated.
For the immunohistochemical (IHC) analysis and detection of proteins of interest the following 
procedure was conducted: Antigen retrieval was achieved by immersing the samples in boiling sodium 
citrate buffer (MW-buffer, pH 6.0, S2031, DAKO) in a microwave. This included two 4 min steps and a 5 min 
step at room temperature in between. In order to block the endogenous peroxidase activity, the tissues were 
incubated in 3% H
2
O
2
 in purified water for 10 min. Furthermore, the tissue was perforated using Tris-buffered 
saline with tween 20 (TBST) buffer for 15 min and potential unspecific antibody binding was prevented via 
a 10 min blocking step with DAKO antibody diluent (S3022, DAKO). In between each of these steps, the 
samples were washed with a TBST buffer for 5 min and a final washing step with phosphate-buffered saline 
(PBS) before the incubation with the following primary antibodies: anti-F4/80 (rat monoclonal, 1:8000, 
MCA497GA, Serotec), anti-CD3 (rabbit polyclonal, 1:250, ab5690, Abcam), anti-alpha smooth muscle actin 
(αSMA) (rabbit polyclonal, 1:500, ab5694, Abcam), anti-vimentin (rabbit monoclonal, 1:2000, ab92547, 
Abcam), collagen type 4, alpha 1 (Col4α1) (rabbit polyclonal, 1:2000, ab6586, Abcam), anti-proliferating cell 
nuclear antigen (PCNA) (rabbit polyclonal, 1:1000, ab18197, Abcam) and anti-cleaved-caspase 3 (cCasp3) 
(rabbit polyclonal, 1:280, 9661S, Cell Signaling). The specificity of the antibodies was ensured by negative 
and positive controls, as well as secondary antibody controls. All primary antibodies were diluted in DAKO 
antibody diluent and incubated over night at 4 °C – except for the anti-CD3 antibody whose incubation 
occurred at room temperature for 1 hour (h). After antibody incubation, the samples were washed three times 
with PBS (5 min each) and Histofine® Simple Stain™ MAX PO, which uses the 3, 3’-diaminobenzidine (DAB) 
chromogen, was applied according to the manufacturer’s protocol (Nichirei). This allowed the visualization 
of the proteins of relevance. Eventually, the tissue samples were counterstained with haematoxylin (Roth) 
and dehydrated in a sequence of ethanol solutions followed by a final xylene dehydration step. The slides 
were then sealed with mounting medium (Histokitt, 1025/500, Hecht) and stored until they were imaged.
The kidneys of all animals in each group were analyzed in a blinded manner to minimize the observer 
bias. Images were taken with an Axio Imager.A1 (Zeiss) microscope at either 20x (all IHC stains) or 40x (PAS 
and SR). The cortex of each kidney sample was screened thoroughly starting at one end of the tissue and 
ending at the other. In order to achieve a concise quantification of the area of interest in a semiautomatic 
manner we used an NIH ImageJ plug-in, which has previously been generated by Gabriel Landini (University 
of Birmingham). This plug-in allows a colour threshold to be set and moreover, the generation of macros 
that can be individually applied to all stored images of each stain to guarantee consistency. The mesangial 
expansion and thus glomerular damage could be visualized with the PAS stain. For this, the PAS+ area of 
at least 20 glomeruli in each animal was analysed. This was done by assessing the glomerular perimeter 
and normalizing the positively stained area to the glomerular capillary tuft area. The SR stain allowed the 
quantification of fibrosis in the renal cortex. At least 15 pictures of each SR-stained kidney were taken and 
the total positively stained area of each visual field was quantified. The F4/80, vimentin, αSMA, Col4α1 
positive areas were measured in the same manner whereas CD3+ as well as PCNA+ cells were counted 
individually using the ImageJ threshold plug-in as previously mentioned.
Quantitative Real-Time (qRT)-PCR.
qRT-PCR was performed as described earlier [32]. Briefly, total RNA was isolated from snap-frozen 
kidney cortex after homogenization with a Precellys 24 homogenizer (Peqlab) using RNeasy RNA isolation 
kit (Qiagen). RNA quality and concentration were determined by a NanoDrop-1000 spectrophotometer 
(Thermo Fisher Scientific). Two micrograms of total renal RNA were transcribed to cDNA (Applied 
Biosystems). Quantitative analysis of target mRNA expression was calculated using the relative standard 
curve method. TaqMan and SYBR green analysis was conducted using an Applied Biosystems 7500 Sequence 
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Detector (Applied Biosystems). The expression levels were normalized to GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) and eEF1α1 (eukaryotic translation elongation factor 1 alpha 1) and mean Ct 
values of each groups are reported (Supplementary Fig. 1). Primer sequences are provided in Supplementary 
Table 1 - for all supplemental material see www.cellphysiolbiochem.com
Statistical analyzes
Statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software). All data are 
presented as mean ± SD and p-values of <0.05 were considered as statistically significant. The p-values in 
the figures are denoted as follows: ns p>0.05, *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Data were 
analyzed by regular two-way ANOVA with Bonferroni’s multiple comparisons test. Data with two groups 
were tested by two-sided unpaired t-test (data with normal distribution).
Results
UUO induces renal damage and apoptosis
Urinary tract obstruction led to hydronephrosis, caused by urine stasis in the renal 
pelvis or calyces in the kidneys (Supplementary Fig. 2). The glomerular and tubular 
basement membrane as well as the brush border of the proximal tubules were visualized by 
the periodic acid Schiff (PAS) staining. The increases in mesangial matrix deposition in the 
glomeruli in both WT UUO and Trpc6-/- UUO versus sham kidneys implicates renal damage 
induced by UUO (Fig. 1A and B). Besides, there were no differences in glomerular injury in WT 
versus Trpc6-/- kidneys upon UUO indicating similar glomerular damage in both genotypes 
(Fig. 1A and B). Next, we stained sections of the kidneys with antibodies against proliferating 
cell nuclear antigen (PCNA) and programmed cell death marker cleaved-caspase 3 (cCasp3). 
UUO-induced increases in PCNA positive (PCNA+) cells and cCasp3 positive (cCasp3+) cells 
were clearly visible in the kidneys of both WT and Trpc6-/- mice (Fig. 2A, C). Although there 
was no difference in the number of PCNA+ cells between UUO WT and Trpc6-/- kidneys (Fig. 
2B), less cCasp3 positive cells were found in Trpc6-/- UUO kidneys compared to WT UUO 
kidneys, indicating that ureteral obstructed Trpc6-/- kidneys show less apoptosis compared 
to obstructed WT kidneys (Fig. 2D).
Fig. 1. PAS stained kidneys. (A): Kidneys stained with the periodic acid Schiff (PAS) stain to detect glomerular 
damage. (B) Quantification of the PAS positive areas in the kidneys. All images were taken at a magnification 
of 40x. Scale bar: 50 μm. All values are means ± SD. ns p>0.05, ***p<0.001 and ****p<0.0001. Wild type 
(WT) and Trpc6-/- sham groups included n=5 kidney samples each. WT and Trpc6-/- UUO-treated groups 
encompassed n=12 (WT) and n=11 (Trpc6-/-) kidney samples. ns, not significant.
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Role of TRPC6-deficiency in renal inflammation
UUO induces immune responses such as infiltration of blood cells leading to renal 
inflammation [4]). Therefore, we determined whether Trpc6-deletion can affect renal 
immune infiltration as well as mRNA expression of pro-inflammatory markers in the 
kidneys. Antibodies against the macrophage marker F4/80 and the T-cell marker CD3 were 
applied in IHC analyses. UUO caused immune cell infiltration in WT and Trpc6-/- kidneys, 
as assessed by F4/80 positive (F4/80+) areas and the numbers of CD3 positive (CD3+) cells 
in the respective kidney sections (Fig. 3A-D). However, cellular infiltration was smaller in 
Trcp6-/- UUO kidneys compared to WT UUO kidneys (Fig. 3A-D) which indicates a protective 
effect when TRPC6 is absent.
Next, we applied qRT-PCR to analyse mRNA expression of the pro-inflammatory markers 
interleukin 1 beta (IL1β), interleukin 6 (IL6) and tumor necrosis factor alpha (TNFα). We 
found that all mentioned markers were significantly increased upon UUO in the renal cortex 
of both WT and Trpc6-/- kidneys (Fig. 4). Surprisingly no differences between Trpc6-/- UUO 
and WT UUO kidneys were seen (Fig. 4A-C).
Fig. 2. Markers of proliferation and apoptosis. (A) Proliferating cell nuclear antigen (PCNA) antibody 
staining: marker of cell regeneration. Arrows show positive cells. All images were taken at a magnification 
of 20x. Scale bar: 100 μm. (B) Quantification of renal cells positively stained for PCNA. (C) Cleaved-caspase 
3 (cCasp3) antibody staining: marker of apoptosis. Arrows show positive cells. All images were taken at a 
magnification of 20x. Scale bar: 100 μm. (D) Quantification of renal cells positively stained for cCasp3. All 
values are means ± SD. ns p>0.05, ***p<0.001 and ****p<0.0001. Wild type (WT) and Trpc6-/- sham groups 
included n=5 kidney samples each. WT and Trpc6-/- UUO-treated groups encompassed n=12 (WT) and n=11 
(Trpc6-/-) kidney samples. ns, not significant.
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Fig. 3. Markers of inflammation in wild-type (WT) and Trpc6-/- kidneys. (A) F4/80 antibody staining: 
macrophage marker. (B) Quantification of the F4/80 positive areas. (C) CD3 antibody staining: T-cell marker. 
Arrows show positive cells (D) Quantification of the CD3 positive cells. WT and Trpc6-/- UUO-treated groups 
encompassed n=12 (WT) and n=11 (Trpc6-/-) kidney samples. All quantification data are means ± SD. ns 
p>0.05, *p<0.05, **p<0.01 and ****p<0.0001. WT and Trpc6-/- sham groups included n=5 kidney samples 
each. All images were taken at a magnification of 20x. Scale bar: 100 μm. ns, not significant.
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Fig. 4. Expression of inflammatory markers in wild-type (WT) and Trpc6-/- kidneys. Renal mRNA levels 
of (A) interleukin 1 beta (IL1β), (B) interleukin 6 (IL6) and (C) tumor necrosis factor alpha (TNFα) in sham-
operated groups and in UUO-operated groups. Renal mRNA expression data were determined in n=5 each 
for sham-operated WT and Trpc6-/- kidneys, n=9 for UUO-operated WT kidneys and n=8 for UUO-operated 
Trpc6-/- kidneys. The relative standard curve method was used for relative quantification. All data are means 
± SD, ns p>0.05, ***p<0.001, ****p<0.0001. ns, not significant.
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Role of TRPC6-deficiency in renal fibrosis
To examine a possible role of TRPC6-deficiency in renal fibrosis, we performed 
histological analysis including IHC and measured gene expression by qRT-PCR. A Sirius red 
(SR) stain was performed and SR positive (SR+) areas were quantified (Fig. 5A, B) to assess 
the degree of collagen deposition in the kidneys. Sham-treated kidneys of either genotype 
exhibited only small areas of SR+ areas (Fig. 5A). In contrast, WT UUO kidneys displayed a 
6-fold increase in SR+ areas compared to controls. This increase in collagen deposition was 
smaller in Trpc6-/- UUO kidneys compared to WT UUO kidneys (Fig. 5B). Next, IHC studies 
were performed using antibodies against collagen type 4 alpha 1 (Col4α1) to determine the 
level of fibrosis, the mesenchymal marker vimentin to identify epithelial-to-mesenchymal 
transition (EMT) of tubular epithelial cells and alpha smooth muscle actin (αSMA) to detect 
myofibroblasts and mesangial cells as indicators of cell types involved in fibrosis (Fig. 5C-
H). We observed a significant increase in Col4α1 positive (Col4α1+) area in UUO kidneys 
compared to sham kidneys of both genotypes (Fig. 5C, D). However, this increase in Col4α1 
positive (Col4α1+) area was smaller in Trpc6-/- UUO kidneys compared to WT UUO kidneys 
Fig. 5. Expression of fibrosis markers. (A) Sirius red (SR) staining (40x, Scale bar: 50 μm). (B) Quantification 
of the SR positive areas. (C) Collagen type 4, alpha 1 (Col4α1) antibody staining: fibrosis marker (20x, Scale 
bar: 100 μm). (D) Quantification of the Col4α1 positive areas. (E) Vimentin antibody staining: mesenchymal 
marker (20x, Scale bar: 100 μm. (F) Quantification of the vimentin positive areas. (G) Alpha smooth muscle 
actin (αSMA) antibody staining: myofibroblast marker (20x, Scale bar: 100 μm). (H) Quantification of the 
αSMA positive areas. Wild type (WT) and Trpc6-/- sham groups included n=5 kidney samples each. WT and 
Trpc6-/- UUO-treated groups encompassed n=12 (WT) and n=11 (Trpc6-/-) kidney samples. All quantification 
data are means ± SD. ns p>0.05, *p<0.05, ***p<0.001 and ****p<0.0001. ns, not significant.
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(Fig. 5C, D). Furthermore, a marked increase in vimentin positive (vimentin+) area (Fig. 5E, F) 
and αSMA positive (αSMA+) area (Fig. 5G, H) was observed in UUO kidneys of both genotypes. 
Again, the increase in vimentin+ mesenchymal cells and αSMA+ myofibroblasts was smaller 
in Trpc6-/- UUO kidneys compared to WT UUO kidneys (Fig. 5E-H). Taken together, these data 
suggest a protective effect in renal fibrosis when TRPC6 is absent.
By using qRT-PCR, we analysed the mRNA expression of pro-fibrotic markers in renal 
cortex, including collagen type 1 alpha 1 (Col1α1), collagen type 3 alpha 1 (Col3α1), collagen 
type 4 alpha 1 (Col4α1), transforming growth factor beta 1 (TGFβ1) and αSMA (Fig. 6). 
Whereas UUO caused increased mRNA expression of all pro-fibrotic markers in the renal 
cortex of WT mice (Fig. 6A-E), Trpc6-deficiency UUO kidneys displayed only a significant 
increase in Col3α1, Col4α1 and TGFβ1 but not αSMA mRNA levels (Fig. 6B, C, D). When we 
compared the mRNA expression of the aforementioned markers within the UUO-treated 
groups, we found that all pro-fibrotic markers except for TGFβ1 were reduced in Trcp6-/- UUO 
kidneys relative to WT UUO kidneys (Fig. 6A-E) supporting the idea that Trpc6-deficiency is 
protective in this kidney disease model.
Expression profile of TRPC channels in renal cortex
The genomic absence of one TRPC channel may affect the expression of the remaining 
which could contribute to the renal outcome. We performed qRT-PCR to first identify the 
relative expression of TRPC family members (TRPC1-7) in renal cortices of WT and Trpc6-
deficient mice. In sham-operated kidneys we found that deletion of Trpc6 was associated 
with reduced Trpc2, Trpc3 and Trpc4 mRNA expression compared to WT kidneys (Fig. 7A-D). 
Conversely, Trpc6-deficiency increased Trpc1 mRNA expression. Similarly, Trpc5 mRNA was 
present in Trpc6-/- kidneys but below detection limit in WT kidneys (Fig. 7E). As reported 
earlier [18], whereas Trpc6 mRNA expression could be determined in WT kidneys it was 
below the detection levels in Trpc6-/- kidneys (Fig. 7F). Trpc7 mRNA was not detectable in 
Fig. 6. Expression of genes involved in renal fibrosis in kidneys of wild-type (WT) and Trpc6-/- mice. Renal 
mRNA levels of (A) collagen type 1, alpha1 (Col1α1), (B) collagen type 3, alpha1 (Col3α1), (C) collagen 
type 4, alpha1 (Col4α1), (D) transforming growth factor beta 1 (TGFβ1) and (E) alpha smooth muscle 
actin (αSMA) in sham-operated groups and in UUO-operated groups. Renal mRNA expression data were 
determined in n=5 each for sham-operated WT and Trpc6-/- mice, n=9 for UUO-operated WT mice and n=8 
for UUO-operated Trpc6-/- mice. The relative standard curve method was used for relative quantification. All 
data are means ± SD., ns p>0.05, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ns, not significant.
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both WT and Trpc6-/- kidneys, but was present in WT brain tissue, which served as positive 
control (Supplementary Fig. 3B).
Next, we determined in WT animals whether the relative expression of TRPC isoforms is 
affected by UUO. Interestingly, ureter obstruction did not affect the relative mRNA expression 
levels of most TRPC family members including Trpc2, Trpc3, Trpc4, and Trpc5 (Fig. 7B-E). In 
contrast UUO provoked an approximately 50% downregulation of Trpc1 and notably a 60% 
upregulation of Trpc6 mRNA expression in WT kidneys (Fig. 7A and F) relative to sham-
operated WT animals.
On the other hand, Trpc6-deficiency provoked a highly significant decrease of Trpc2 and 
Trpc4 transcript levels in both sham and UUO kidneys (Fig. 7B, D) whereas Trpc1 and Trpc3 
mRNA levels showed significant differences under sham conditions compared to WT (Fig. 
7A, C), in UUO kidneys their level was similar. In addition, Trpc5 transcript levels were below 
detection levels in the presence and absence of Trpc6 (Fig. 7E), and as expected in Trpc6-/- 
kidneys lacking Trpc6 mRNA (Fig. 7F).
UUO in NZO mice
We next used the complex disease NZO mouse model to evaluate UUO nephropathy 
and regulation of TRPC channel expression in an inbred obese mouse strain carrying 
susceptibility genes for diabetes and hypertension. In NZO mice, UUO caused also significant 
damage to the kidney. Histological analyses showed that UUO induced increases in PAS+ area, 
PCNA+ cells, SR+ area, F4/80+ area and CD3+ cells (Fig. 8). Furthermore, we detected an UUO-
induced increase in mRNA expression of the pro-fibrotic markers Col1α1, Col3α1, Col4α1 
and TGFβ1 (Fig. 9A) and the pro-inflammatory markers IL1β, IL6, TNFα, ICAM1, VCAM1 and 
MCP1 relative to the sham-operated group (Fig. 9B).
We also examined the relative expression profile of TRPC genes in kidneys of NZO mice 
in sham and UUO kidneys by qRT-PCR. NZO sham kidneys expressed mRNA of six TRPC 
genes in renal cortex (Fig. 10). UUO caused, similarly to the previous findings in WT mice, 
up-regulation of Trpc6 mRNA expression while Trpc1 and Trpc5 mRNA expression was 
Fig. 7. Expression of renal TRPC channels in wild-type (WT) and Trpc6-/- mice.  Renal mRNA levels of (A) 
transient receptor potential cation channel 1 (TRPC1), (B) TRPC2 (C) TRPC3 (D) TRPC4 (E) TRPC5 and 
(F) TRPC6 in sham-operated groups and in UUO-operated groups. Renal mRNA expression data were 
determined in n=5 each for sham-operated WT and Trpc6-/- mice, n=9 for UUO-operated WT mice and n=8 
for UUO-operated Trpc6-/- mice. The relative standard curve method was used for relative quantification. All 
data are means ± SD., ns p>0.05, **p<0.01, ***p<0.001, ****p<0.0001. ns, not significant; n.d., not detected.
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down-regulated. There was no change in Trpc2 and Trpc3 mRNA expression in NZO kidneys 
upon UUO surgery (Fig. 10). Noteworthy, Trpc7 mRNA was not detectable in NZO kidneys 
without and in response to UUO (Fig. 10), which is in line with our findings in WT and 
Trpc6-/- kidneys (Supplementary Fig. 3).
Discussion
Renal fibrosis and inflammation
Mechanisms that promote kidney disease progression include renal atrophy, fibrosis and 
increased leukocyte infiltration into the kidneys [33, 34]. Renal fibrosis and inflammation are 
two histological hallmarks of progressive kidney disease and specific antibody staining is a 
common tool to estimate renal damage [35, 36]. UUO  is an established model for renal fibrosis 
and chronic kidney failure [4]. TRPC6, which is regarded a major slit diaphragm-associated 
channel, can be increasingly detected in various kidney diseases such as FSGS [37, 38], diabetic 
nephropathy [22, 39-41], minimal change nephrosis [38, 42] and membranous nephropathy 
Fig. 8. Markers 
of fibrosis and 
inflammation in 
New Zealand obese 
(NZO) mice. (A) 
Periodic acid Schiff 
(PAS) stain: marker 
of glomerular 
damage (40x). 
Scale bar: 50 μm. 
Proliferating cell 
nuclear antigen 
(PCNA) antibody 
stain: marker of 
cell regeneration 
(20x. Scale bar: 
100 μm; arrows 
show positive cells). 
Sirius red (SR) 
stain: marker of 
interstitial fibrosis 
(40x. Scale bar: 
50 μm). F4/80 
antibody stain: 
macrophage marker 
(20x. Scale bar: 
100 μm) and CD3 
antibody stain: 
T-cell marker (20x. 
Scale bar: 100 
μm; arrows show 
positive cells) in 
s h a m - o p e r a t e d 
group and UUO-
operated groups. 
(B) All quantification data are means ± SD. Data were determined in n=5 for sham-operated kidneys, n=10 
for UUO-operated kidneys. **p<0.01, ***p<0.001 and ****p<0.0001.
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[42-44]. In previous studies, TRPC6 was 
reported to contribute to fibroblast-
to-myofibroblast transdifferentiation 
(FMT) and is thought to promote tissue 
scarring [45-47]. Some study suggest 
that TRPC6  as a non-selective cation 
channel can be responsible for increased 
Ca2+ flux in myo-/fibroblasts [48]. Recent 
studies show that TRPC6 is involved in 
the pathogenesis of kidney fibrosis and 
genomic inhibition of the channel can 
reduce rat kidney fibroblast proliferation 
and myofibroblast differentiation in vitro 
[49]. As our study was undergoing, Wu, et 
al [18]. reported that inhibition of TRPC6 
can ameliorate renal fibrosis in the mice 
based on UUO model. In the present 
study, we used Trpc6-/- mice and equally 
carried out UUO surgery to induce early 
stage CKD. We found similarly to Wu et 
al. that Trpc6 loss reduces renal fibrosis 
in the murine UUO model. In addition, we 
were able to show that TRPC6-deficiency caused a decreased mRNA expression of multiple 
pro-fibrotic genes. Our results therefore confirm the previous finding that Trpc6 deletion 
attenuates UUO-induced kidney fibrosis in mice [18].
The renal damage occurring in CKD is, at least in part, promoted by the immune system 
[50]. Most kidney diseases involve an accumulation of immune cells of the innate (e.g. 
macrophages and neutrophils) and adaptive (e.g. T-cells) immune system. In particular, 
tubulointerstitial monocyte immune infiltration can mediate tissue remodeling that 
Fig. 9. Expression of markers of fibrosis and inflammation in New Zealand obese (NZO) mice. (A) Renal 
mRNA levels of fibrosis markers: collagen type 1, alpha 1 (Col1α1), collagen type 3, alpha 1 (Col3α1), 
collagen type 4, alpha 1 (Col4α1) and transforming growth factor beta 1 (TGFβ1) in sham-operated group 
and in UUO-operated group. (B) Renal mRNA levels of inflammation markers: interleukin 1 beta (IL1β), 
interleukin 6 (IL6), tumor necrosis factor alpha (TNFα), intercellular adhesion molecule 1 (ICAM1), vascular 
cell adhesion molecule 1 (VCAM1) and monocyte chemotactic protein 1 (MCP1) in sham-operated group 
and UUO-operated groups. All mRNA expression data are determined in n=5 for sham-operated kidneys, 
n=9 for UUO-operated kidneys. The relative standard curve method was used for relative quantification. All 
data are means ± SD., **p<0.01, ***p<0.001, ****p<0.0001 and ****p<0.0001.
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Fig. 10. Expression of renal TRPC channels in New 
Zealand obese (NZO) mice. Renal mRNA levels of 
TRPC1-7 channels in sham-operated group and in 
UUO-operated group. Renal mRNA expression data 
were determined in n=5 sham-operated kidneys, n=9 
UUO-operated kidneys. The relative standard curve 
method was used for relative quantification. All data 
are means ± SD, ns p>0.05, **p<0.01, ns: not significant. 
n.d.: not detected.
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ultimately promotes fibrogenesis, renal atrophy and thus, kidney failure [51-53]. Our results 
revealed a less infiltration of CD3 cells and F4/80+ area in UUO Trpc6-/- kidneys compared 
to those in UUO WT kidneys. We have therefore performed qPCR analysis in our model as 
well to quantify inflammatory cytokine levels. Whereas, UUO provoked an increase in mRNA 
expression of the pro-inflammatory markers in both Trpc6-/- and WT kidneys we did not find 
a significant beneficial effect of lacking Trpc6 on the expression of pro-inflammatory markers 
at the mRNA level upon UUO surgery. This might be because we collected tissues only at day 
7 after induction of UUO and therefore we might have missed the time-point where lacking 
Trpc6 influence pro-inflammatory gene expression. On the other side it lacking Trpc6 can 
influence immune cell function and therefore pro-inflammatory cytokine expression [54]. 
Taken together, our data point to a complex (in-)direct contribution of TRPC6 to renal 
inflammation in the UUO model.
To estimate renal apoptosis as well as regenerative potential, kidney sections were 
stained with antibodies against the apoptosis marker cleaved-caspase 3 (cCasp3) and the 
mitosis marker proliferating cell nuclear antigen (PCNA). Since cCasp3 and PCNA levels 
correlate positively with renal injury, they are commonly used to determine the degree 
of renal damage under chronic damaging conditions [55-57]. It is known that chronic 
activation of TRPC6 is positively correlated with the rate of apoptosis in cells such as 
podocytes [58, 59] and endothelial cells [60]. Indeed, we found less cCasp3 positive cells in 
kidneys of Trpc6-/- mice underwent UUO. It might however reflect the less inflammatory cell 
infiltration, since cCasp positive cells were count in the whole kidney section irrespective of 
the signal’s origin. PCNA is known as a probe for the detection of cell proliferative activity 
[61]. In our study, PCNA+ cells were found to be increased after UUO in both WT and Trpc6-/- 
kidneys. Nevertheless, we did not find significant difference in PCNA+ cells between WT and 
Trpc6-/- mice. Correlated with the result of cCasp3 cell infiltration, it might be due to an 
imbalance between cell apoptosis and proliferative activity, or it might be because PCNA 
is also regulated by other factors, e.g. p53[62] and DNA damage binding protein 2 (DDB2)
[63]. In summary, the results indicate that TRPC6-deficiency protects renal cells from UUO-
induced apoptosis.
In summary – based on our key findings of reduced renal fibrosis and inflammation 
after UUO in the Trpc6-/- mice, we believe that these changes are associated with improved 
kidney function, which ultimately should delay CKD progression to end stage renal disease. 
Therefore, we suggest that non-cell specific TRPC6 inhibition seems to be meaningful 
therapeutic approach to improve the outcome of CKD. However, further studies are needed 
to evaluate this approach in other experimental models of CKD.
TRPC6 and other TRPCs
We further revealed that TRPC6-deficiency per se impacts on renal TRPC channel 
expression in mice as indicated by reduced mRNA expression of TRPC2, TRPC3 and TRPC4 
and increased mRNA expression of TRPC1. Moreover, we found that UUO caused reduced 
Trpc1 mRNA and increased Trpc6 mRNA expression without changes of Trpc3 expression in 
WT kidneys. Collectively, the data suggest that counterbalanced or increased expression of 
TRPC1 and TRPC6 could play a role in UUO-induced kidney damage. Since genomic deletion 
of Trpc6 improved renal fibrosis and was associated with an increase of Trpc1 mRNA 
expression and a reduction of Trpc2, Trpc3 and Trpc4 mRNA expression in sham-operated 
kidneys to levels similar or greater than those observed in UUO kidneys, we conclude that 
TRPC6 could drive renal fibrosis with or without modifying effects of TRPC1/2/3/4. Our 
studies revealed an unrecognized renal counter-regulation of TRPC5 and TRPC7 gene 
expression. This conclusion is supported by findings that TRPC5 and TRPC7 is not expressed 
in normal kidneys of mice [64].
Of note, the data in the present study shows that the deficiency for TRPC6 is associated 
with reduced Trpc3 mRNA expression in Trpc6-/- kidneys compared to WT kidneys, which 
disappears in obstructive nephropathy. At a first glance, this is surprising as we observed in 
our previous studies on Trpc6-/- mice that loss of TRPC6 is associated with up-regulation of 
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constitutively active TRPC3-type channels in some arteries [27]. However, to our knowledge, 
TRPC channels (TRPC1-7) expression and resulting putative (functional) counterbalancing 
effects have not been investigated in experimental obstructive nephropathy. This is of 
particular interest for TRPC3, which is capable of contributing to fibrogenesis and tissue 
inflammation [65-69]. Additionally, Wu et al. reported that TRPC3 mRNA expression is 
upregulated in UUO-induced renal fibrosis [18]. However, we could not detect an increase 
in TRPC3 expression level in WT kidneys (neither in our NZO mouse model) which argues 
against an important role in progression of fibrosis in obstructive nephropathy. Based on 
our findings, it is unlikely that increased TRPC3 expression upon UUO accounts for the 
beneficial role of TRPC6-deficiency in this model of kidney failure. These mechanisms 
might be particularity relevant for inherited FSGS caused by mutations in TRPC6 [6, 70]. 
This conclusion is supported by recent findings demonstrating that knockout of both TRPC3 
and TRPC6 did not diminish UUO-induced fibrosis more than deletion of TRPC6 alone [18]. 
BTP2, an inhibitor of several TRPC channels, including TRPC3 and TRPC6, had an effect 
similar to that of Trpc6 knockout on fibrosis, but also attenuated the up-regulation of TRPC6 
expression, suggesting that TRPC6 channel activity may induce its own gene expression in 
the UUO model [2] and promote fibrosis in this model. Nevertheless, future studies using 
more specific TRPC3/6 blockers are necessary to clarify the contribution of TRPC3 in the 
absence and presence of functional TRPC6 channels. Recently, novel TRPC6 blockers have 
been developed [71-73], which could represent important tools to evaluate the role of TRPC6 
in these conditions.
Diabetic nephropathy
Today, 25-40% of diabetic patients suffer from diabetic nephropathy [74, 75]. Thus, 
diabetic patients can be considered as high-risk patients for the development of chronic 
kidney disease. Diabetic nephropathy shows pronounced glomerular changes that are 
present in patients with long-standing diabetes often even before the detection of albumin in 
the urine. Several mechanisms that can lead to diabetic nephropathy are under discussion. We 
evaluated whether UUO-operated NZO mouse model could represent a model of progressive 
nephropathy in co-morbid conditions of obesity, hypertension and type 2 diabetes [24], 
which had not been reported before. Our study shows that UUO can successfully induce renal 
fibrosis and inflammatory infiltration in the NZO mouse model (NZO/HIBomDife) carrying 
susceptibility genes for obesity, diabetes and hypertension.
More importantly, our study also suggests that Trpc1-4 and Trpc6 expression in NZO 
mice underwent UUO/sham-operation showed similar tendency to those observed in WT 
mice, which verified the regulation of TRPC channels in a second mouse model. Interestingly, 
we found that Trpc5 expression was detected in the kidneys of NZO mice, which indicated 
that TRPC5 could be specifically involved in this process in NZO mice. Our results suggest that 
the UUO-operated NZO mouse model might represent a valuable mouse model to be used to 
evaluate the specific contribution of TRPC6 and other TRPC channel subfamilies in the renal 
injury upon obesity, hypertension and diabetes. This approach could take advance of testing 
better, i.e. TRPC subfamily specific blockers and agonists. In spite of recent progress in this 
field [71-73, 76], we are optimistic that those drugs are becoming available in the near future 
for in vivo testing.
Conclusion
Our study observed that inhibition of TRPC6 is associated with a decrease in inflammatory 
cell infiltration in murine UUO model for the first time. Also, the findings are in line with 
the concept that up-regulation of TRPC6 contributes to fibrosis in UUO kidneys. The results 
support the view that increased TRPC6 expression can play an important pathophysiological 
role in the development of progressive kidney disease [14, 38, 77, 78]. Moreover, the present 
results imply that the genomic loss of TRPC6 is associated with dysregulation of multiple 
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TRPC channels (TRPC1-4) under chronic kidney damaging conditions, which could represent 
additional drivers of renal fibrosis and chronic kidney disease. Our results show that UUO 
causes also up-regulation of TRPC6 in kidneys of NZO mice, which implies that inhibition of 
TRPC6 is also a promising therapeutic strategy for treatment of renal fibrosis and immune 
cell infiltration in polygenic models for the human metabolic syndrome.
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